This post was originally published on this site
Just to recap, CRISPR’s mission is to develop “transformative gene-based medicines for serious diseases.” The company’s pipeline of therapeutic candidates address serious conditions such as sickle-cell disease and beta thalassemia.
As we’ll see, CRSP stock is definitely on a downtrend. Momentum-focused traders might choose to stay away, but if you’re a dyed-in-the-wool value investor, then you should find a compelling opportunity with CRISPR Therapeutics.
